News | November 11, 2024
Aurobindo Pharma Q2 FY25 net profit up 8.6% at Rs. 817 Cr
Growth markets revenue increased by 44 YoY to Rs. 812 crore
Growth markets revenue increased by 44 YoY to Rs. 812 crore
USFDA completes PAI of Lupin’s biotech facility in Pune
The product is expected to be launched in Q3FY25
The sANDA was submitted as “Prior Approval Supplement” for addition of an alternate drug product manufacturing, labeling, packaging, and testing facility
Revenue from Operations increased by 10.5% YoY to Rs. 7,567 crore with growth across the businesses
The approved product has an estimated market size of US$ 268 million for the twelve months ending June 2024, according to IQVIA
These facilities are commissioned by Aurobindo's wholly own subsidiary: Lyfius Pharma Private Limited, Qule Pharma Private Limited, Eugia Steriles Private Limited and Auroactive Pharma Private Limited.
The approved product has an estimated market size of US$ 44.5 million for the twelve months ending January 2024
Earlier, he worked with Cadila Pharmaceuticals Limited, Cipla, Alkem Laboratories, and Wockhardt, and started his career with Novartis
The product will be launched in March 2024
Subscribe To Our Newsletter & Stay Updated
